STATEMENT UNDER 37 CER 3.73(b)
`
`Applicant/Patent Owner, Frank Misselwitz
`
`Application No/PatentNo.:9,539,218ss s*Filed/Issue Date: 01-10-2017
`Titled:
`
`Prevention and Treatment of Thromboembolic Disorders
`
`BAYER INTELLECTUAL PROPERTY GMBH
`(Nameof Assignee)
`
`/a
`
`corporation
`(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
`
`states thatit is:
`
`the assignee of the entire right, title, and interest in;
`
`2. [|
`
`an assigneeofless than the entire right,title, and interest in
`(The extent (by percentage)of its ownership interestis
`
`%); or
`
`PTO/SB/96 (07-09)
`Approvedfor use through 07/31/2012. OMB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`
`
`
`3. [|
`
`the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
`
`the patent application/patentidentified above, by virtue of either:
`
`A. [|
`
`OR
`
`B.
`
`An assignmentfrom the inventor(s) of the patent application/patent identified above. The assignment was recordedin
`the United States Patent and Trademark Office at Reel
`, Frame
`, or for which a
`copy therefore is attached.
`
`A chain oftitle from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
`
`1.From:
`
`inventors
`
`To: BAYER HEALTHCARE AG
`
`The document wasrecorded in the United States Patent and TrademarkOffice at
`
`Reel 020979
`
`Frame 0627
`
`,
`
`or for which a copythereof is attached.
`
`2.From: BAYER HEALTHCARE AG
`
`To: BAYER SCHERING PHARMA AG
`
`The document wasrecorded in the United States Patent and TrademarkOffice at
`
`Reel 022520
`
`,
`
`Frame 0150
`
`,
`
`or for which a copy thereofis attached.
`
`3. From: BAYER HEALTHCARE AG
`
`To: BAYER SCHERING PHARMA AG
`
`The document wasrecorded in the United States Patent and TrademarkOffice at
`
`Reel 022575
`
`_
`
`Frame 0337
`
`,
`
`or for which a copythereofis attached.
`
`Additional documentsin the chain oftitle are listed on a supplemental sheet(s).
`
`As required by 37 CFR 3.73(b)(1)(i), the documentary evidenceof the chain oftitle from the original owner to the assignee was,
`or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
`
`[NOTE: A separate copy (/.e., a true copy of the original assignment document(s)) must be submitted to AssignmentDivision in
`accordance with 37 CFR Part 3, to record the assignmentin the records of the USPTO. See MPEP 302.08]
`
`The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
`
`/Christine M. Hansen/
`Signature
`
`October 15, 2018
`Date
`
`Attorney of Record 40634
`Christine M. Hansen
`Title
`Printed or Typed Name
`This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public whichisto file (and by the USPTO to
`process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including
`gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending uponthe individual case. Any comments on the amountoftime
`you require to complete this form and/or suggestions for reducing this burden, should be sentto the Chief Information Officer, U.S. Patent and Trademark Office, U.S.
`Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner
`for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection
`with your submission of the attached form related to a patent application or patent. Accordingly,
`pursuant to the requirements of the Act, please be advised that:
`(1) the general authority for the
`collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary;
`and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark
`Office is to process and/or examine your submission related to a patent application or patent. If you do
`not furnish the requested information, the U.S. Patent and Trademark Office may not be able to
`process and/or examine your submission, which mayresult in termination of proceedings or
`abandonmentof the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed under the
`Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from
`this system of records maybe disclosed to the Department of Justice to determine whether
`disclosure of these records is required by the Freedom ofInformation Acct.
`in the course of
`A record from this system of records may be disclosed, as a routine use,
`presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to
`opposing counsel in the course of settlement negotiations.
`to a Member of
`A record in this system of records may be disclosed, as a routine use,
`Congress submitting a request involving an individual, to whom the record pertains, when the
`individual has requested assistance from the Member with respect to the subject matter of the
`record.
`A record in this system of records may be disclosed, as a routine use, to a contractor of the
`Agency having need for the information in order to perform a contract. Recipients of
`information shall be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed under the Patent Cooperation Treaty in
`this system of records may be disclosed, as a routine use, to the International Bureau of the
`World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal
`agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to
`the Atomic Energy Act (42 U.S.C. 218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator,
`General Services, or his/her designee, during an inspection of records conducted by GSA as
`part of that agency's responsibility to recommend improvements in records management
`practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall
`be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not
`be used to make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public after
`either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent
`pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37
`CFR 1.14, aS a routine use, to the public if the record wasfiled in an application which
`became abandonedor in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspection or an
`issued patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State,
`or local law enforcement agency, if the USPTO becomes awareof a violation or potential
`violation of law or regulation.
`
`